Cargando…

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients

Tumor cells shed an abundance of extracellular vesicles (EVs) to body fluids containing bioactive molecules including DNA, RNA, and protein. Investigations in the field of tumor-derived EVs open a new horizon in understanding cancer biology and its potential as cancer biomarkers as well as platforms...

Descripción completa

Detalles Bibliográficos
Autores principales: Hur, Jae Young, Kim, Hee Joung, Lee, Jong Sik, Choi, Chang-Min, Lee, Jae Cheol, Jung, Min Kyo, Pack, Chan Gi, Lee, Kye Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787306/
https://www.ncbi.nlm.nih.gov/pubmed/29374476
http://dx.doi.org/10.1186/s12943-018-0772-6
_version_ 1783295909893767168
author Hur, Jae Young
Kim, Hee Joung
Lee, Jong Sik
Choi, Chang-Min
Lee, Jae Cheol
Jung, Min Kyo
Pack, Chan Gi
Lee, Kye Young
author_facet Hur, Jae Young
Kim, Hee Joung
Lee, Jong Sik
Choi, Chang-Min
Lee, Jae Cheol
Jung, Min Kyo
Pack, Chan Gi
Lee, Kye Young
author_sort Hur, Jae Young
collection PubMed
description Tumor cells shed an abundance of extracellular vesicles (EVs) to body fluids containing bioactive molecules including DNA, RNA, and protein. Investigations in the field of tumor-derived EVs open a new horizon in understanding cancer biology and its potential as cancer biomarkers as well as platforms for personalized medicine. This study demonstrates that successfully isolated EVs from plasma and bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients contain DNA that can be used for EGFR genotyping through liquid biopsy. In both plasma and BALF samples, liquid biopsy results using EV DNA show higher accordance with conventional tissue biopsy compared to the liquid biopsy of cfDNA. Especially, liquid biopsy with BALF EV DNA is tissue-specific and extremely sensitive compared to using cfDNA. Furthermore, use of BALF EV DNA also demonstrates higher efficiency in comparison to tissue rebiopsy for detecting p.T790 M mutation in the patients who developed resistance to EGFR-TKIs. These finding demonstrate possibility of liquid biopsy using EV DNA potentially replacing the current diagnostic methods for more accurate, cheaper, and faster results. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12943-018-0772-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5787306
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57873062018-02-08 Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients Hur, Jae Young Kim, Hee Joung Lee, Jong Sik Choi, Chang-Min Lee, Jae Cheol Jung, Min Kyo Pack, Chan Gi Lee, Kye Young Mol Cancer Letter to the Editor Tumor cells shed an abundance of extracellular vesicles (EVs) to body fluids containing bioactive molecules including DNA, RNA, and protein. Investigations in the field of tumor-derived EVs open a new horizon in understanding cancer biology and its potential as cancer biomarkers as well as platforms for personalized medicine. This study demonstrates that successfully isolated EVs from plasma and bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients contain DNA that can be used for EGFR genotyping through liquid biopsy. In both plasma and BALF samples, liquid biopsy results using EV DNA show higher accordance with conventional tissue biopsy compared to the liquid biopsy of cfDNA. Especially, liquid biopsy with BALF EV DNA is tissue-specific and extremely sensitive compared to using cfDNA. Furthermore, use of BALF EV DNA also demonstrates higher efficiency in comparison to tissue rebiopsy for detecting p.T790 M mutation in the patients who developed resistance to EGFR-TKIs. These finding demonstrate possibility of liquid biopsy using EV DNA potentially replacing the current diagnostic methods for more accurate, cheaper, and faster results. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12943-018-0772-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-27 /pmc/articles/PMC5787306/ /pubmed/29374476 http://dx.doi.org/10.1186/s12943-018-0772-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Hur, Jae Young
Kim, Hee Joung
Lee, Jong Sik
Choi, Chang-Min
Lee, Jae Cheol
Jung, Min Kyo
Pack, Chan Gi
Lee, Kye Young
Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
title Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
title_full Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
title_fullStr Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
title_full_unstemmed Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
title_short Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
title_sort extracellular vesicle-derived dna for performing egfr genotyping of nsclc patients
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787306/
https://www.ncbi.nlm.nih.gov/pubmed/29374476
http://dx.doi.org/10.1186/s12943-018-0772-6
work_keys_str_mv AT hurjaeyoung extracellularvesiclederiveddnaforperformingegfrgenotypingofnsclcpatients
AT kimheejoung extracellularvesiclederiveddnaforperformingegfrgenotypingofnsclcpatients
AT leejongsik extracellularvesiclederiveddnaforperformingegfrgenotypingofnsclcpatients
AT choichangmin extracellularvesiclederiveddnaforperformingegfrgenotypingofnsclcpatients
AT leejaecheol extracellularvesiclederiveddnaforperformingegfrgenotypingofnsclcpatients
AT jungminkyo extracellularvesiclederiveddnaforperformingegfrgenotypingofnsclcpatients
AT packchangi extracellularvesiclederiveddnaforperformingegfrgenotypingofnsclcpatients
AT leekyeyoung extracellularvesiclederiveddnaforperformingegfrgenotypingofnsclcpatients